{"name":"Azienda Ospedaliero-Universitaria di Modena","slug":"azienda-ospedaliero-universitaria-di-modena","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Recombinant LH (Luveris)","genericName":"Recombinant LH (Luveris)","slug":"recombinant-lh-luveris","indication":"Infertility in women with LH and FSH deficiency undergoing assisted reproductive technology","status":"marketed"},{"name":"No Treatment Added","genericName":"No Treatment Added","slug":"no-treatment-added","indication":"Other","status":"phase_3"},{"name":"Pain killer","genericName":"Pain killer","slug":"pain-killer","indication":"Other","status":"marketed"},{"name":"long GnRH agonist or flexible GnRH antagonist protocol.","genericName":"long GnRH agonist or flexible GnRH antagonist protocol.","slug":"long-gnrh-agonist-or-flexible-gnrh-antagonist-protocol","indication":"Other","status":"marketed"},{"name":"peritoneal dialysate at 37°C temperature","genericName":"peritoneal dialysate at 37°C temperature","slug":"peritoneal-dialysate-at-37-c-temperature","indication":"End-stage renal disease (ESRD) requiring renal replacement therapy","status":"marketed"}]}],"pipeline":[{"name":"Recombinant LH (Luveris)","genericName":"Recombinant LH (Luveris)","slug":"recombinant-lh-luveris","phase":"marketed","mechanism":"Recombinant luteinizing hormone (LH) stimulates the ovaries to produce estrogen and progesterone, promoting follicle development and ovulation in women with LH deficiency.","indications":["Infertility in women with LH and FSH deficiency undergoing assisted reproductive technology","Anovulation or oligo-ovulation in women with hypogonadotropic hypogonadism"],"catalyst":""},{"name":"No Treatment Added","genericName":"No Treatment Added","slug":"no-treatment-added","phase":"phase_3","mechanism":"No Treatment Added is a control arm representing standard care without an investigational therapeutic intervention.","indications":[],"catalyst":""},{"name":"Pain killer","genericName":"Pain killer","slug":"pain-killer","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"long GnRH agonist or flexible GnRH antagonist protocol.","genericName":"long GnRH agonist or flexible GnRH antagonist protocol.","slug":"long-gnrh-agonist-or-flexible-gnrh-antagonist-protocol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"peritoneal dialysate at 37°C temperature","genericName":"peritoneal dialysate at 37°C temperature","slug":"peritoneal-dialysate-at-37-c-temperature","phase":"marketed","mechanism":"Peritoneal dialysate at 37°C facilitates the removal of uremic waste products and excess fluid from the blood across the peritoneal membrane during peritoneal dialysis.","indications":["End-stage renal disease (ESRD) requiring renal replacement therapy","Acute kidney injury in select patients"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9jdVczODVTWHpueHloSnIwdWFNMXMxb2dCX2R4VXNVa0kzQWNZU0wtVS1JSVNtUzNCZGxLZGwzSkpEWkY5UExaaUxSQ0tJZFVvNGhNM2JpOFpJNkEzSmdF?oc=5","date":"2025-11-18","type":"trial","source":"nature.com","summary":"Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary end","headline":"Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagn","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBINFZBbHQydGpuTXJ4UTBRTGFiMi01VU5VT3M3cHUwVXJJVkhfdTU3cEZ4S0k3V21SNk9nWWc2bjl4c283dHc4SmJmcDFnSGw5NkVPaUVOSzNYQjJ6QzlN?oc=5","date":"2025-11-07","type":"trial","source":"nature.com","summary":"The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial | Leukemia - nat","headline":"The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term re","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1IWW1VRm5WZURDRHg5cElHSFcyc21XQnV0ci11VXZJM1lUdUhzbFNTbTBMdFFLdkRzSmFXc3drVzduczAtLXNQMVJDdzdYOHlKVjJkN2k5ZFNlT2tSVTk0?oc=5","date":"2023-08-17","type":"trial","source":"nature.com","summary":"Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis - nature.com","headline":"Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9ubklVTHNsLS1ZQU9jVnJHUjRBamFZdE9SSEhjcEdiWER3d1QtVUtjTFQzNXhjZ2RHbXYzMU56azB6VC1lM2ItOURtekhPMDA5OUp0c3lQeEtMZkZ0bkRJ?oc=5","date":"2023-02-16","type":"trial","source":"nature.com","summary":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial - nature.com","headline":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":4,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}